MatthewLShermanMD

PubMed

• 25 citations
  Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
  Sebastian Bauer, Robin L Jones, Jean-Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John R Zalcberg, Yoon-Koo Kang, Albiruni Abdul...> ;Journal of Clinical Oncology. 2022 Dec 1
• 18 citations
  Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
  John Zalcberg, Michael Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina Z. D'Amato, Pin...> ;The Oncologist. 2021 Nov 1
• 274 citations
  Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
  Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia-Manero, Rena Buckstein, Valeria Santini, María Díez-Campelo, Carlo Finelli, Mario Cazzola, Osman Ilha...> ;The New England Journal of Medicine. 2020 Jan 8
• 18 citations
  A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
  Martin H. Voss, Rupal S. Bhatt, Nicholas J. Vogelzang, Mayer Fishman, Robert S. Alter, Brian I. Rini, J. Thaddeus Beck, Monika Joshi, Ralph J. Hauke, Michael B. Atkins...> ;Cancer. 2019 Jul 15
• 72 citations
  Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
  Antonio Piga, Silverio Perrotta, Maria Rita Gamberini, Ersi Voskaridou, Angela Melpignano, Aldo Filosa, Vincenzo Caruso, Antonello Pietrangelo, Filomena Longo, Immacol...> ;Blood. 2019 Mar 21
• 11 citations
  A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
  Ghassan K. Abou-Alfa, Rebecca A. Miksad, Mohamedtaki Abdulaziz Tejani, Stephen K. Williamson, Martin Gutierrez, Olugbenga Olowokure, Manish R. Sharma, Imane El Dika, M...> ;The Oncologist. 2019 Feb 1
• 41 citations
  Locally acting ACE-083 increases muscle volume in healthy volunteers.
  Chad E. Glasser, Michael R. Gartner, Dawn Wilson, Barry Miller, Matthew L. Sherman, Kenneth M. Attie> ;Muscle & Nerve. 2018 Mar 15
• 202 citations
  Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with l...
  Uwe Platzbecker, Ulrich Germing, Katharina Götze, Philipp Kiewe, Karin Mayer, Jörg Chromik, Markus P. Radsak, Thomas Wolff, Xiaosha Zhang, Abderrahmane Laadem, Matthew...> ;The Lancet. Oncology. 2017 Oct 1
• 18 citations
  The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
  Martin H. Voss, Rupal S. Bhatt, Elizabeth R. Plimack, Brian I. Rini, Robert S. Alter, J. Thaddeus Beck, Dawn Wilson, Xiaosha Zhang, Musa Mutyaba, Chad E. Glasser, Kenn...> ;Clinical Cancer Research. 2017 Jul 15
• 148 citations
  Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
  Craig Campbell, Hugh J. McMillan, Jean K. Mah, Mark A. Tarnopolsky, Kathryn Selby, Ty McClure, Dawn Wilson, Matthew L. Sherman, Diana M. Escolar, Kenneth M. Attie> ;Muscle & Nerve. 2017 Apr 1
• 28 citations
  A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
  Antonio Jimeno, Marshall R. Posner, Lori J. Wirth, Nabil F. Saba, Roger B. Cohen, Elizabeta C. Popa, Athanassios Argiris, Kenneth F. Grossmann, Ammar Sukari, Dawn Wils...> ;Cancer. 2016 Dec 1
• 43 citations
  Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with pl...
  Haralambos Raftopoulos, Abderrahmane Laadem, Paul J. Hesketh, Jerome H. Goldschmidt, Nashat Gabrail, Cynthia Osborne, Muhammad Ali, Matthew L. Sherman, Ding Wang, John...> ;Supportive Care in Cancer. 2016 Apr 1
• 82 citations
  A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.
  Kenneth M. Attie, Mark J. Allison, Ty McClure, Ingrid E. Boyd, Dawn Wilson, Amelia E. Pearsall, Matthew L. Sherman> ;American Journal of Hematology. 2014 Jul 1
• 89 citations
  Sotatercept in patients with osteolytic lesions of multiple myeloma.
  Kudrat M. Abdulkadyrov, Galina Salogub, Nuriet K. Khuazheva, Matthew L. Sherman, Abderrahmane Laadem, Rachel Barger, Robert Knight, Shankar Srinivasan, Evangelos Terpos> ;British Journal of Haematology. 2014 Jun 1
• 46 citations
  Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer
  Johanna C. Bendell, Michael S. Gordon, Herbert Hurwitz, Suzanne F. Jones, David S. Mendelson, Gerard C. Blobe, Neeraj Agarwal, Carolyn H. Condon, Dawn Wilson, Amelia E...> ;Clinical Cancer Research. 2014 Jan 15
• 71 citations
  Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women
  Matthew L. Sherman, Niels Borgstein, Louisa Mook, Dawn Wilson, Yijun Yang, Nianhang Chen, Ravindra Kumar, Kenneth Kim, Abderrahmane Laadem> ;Journal of Clinical Pharmacology. 2013 Nov 1
• 124 citations
  A single ascending-dose study of muscle regulator ace-031 in healthy volunteers
  Kenneth M. Attie, Niels Borgstein, Yijun Yang, Carolyn H. Condon, Dawn Wilson, Amelia E. Pearsall, Ravi Kumar, Debbie A. Willins, Jas Seehra, Matthew L. Sherman> ;Muscle & Nerve. 2013 Mar 1
• 53 citations
  Activin receptor antagonists for cancer-related anemia and bone disease.
  Scott Z. Fields, Shiroo Parshad, Madhurima Anne, Haralambos Raftopoulos, Mark J. Alexander, Matthew L. Sherman, Abderrahmane Laadem, Victoria Sung, Evangelos Terpos> ;Expert Opinion on Investigational Drugs. 2013 Jan 1
• Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors.
  Bendell JC, Gordon MS, Hurwitz H, Condon CH, Yang Y, Wilson D, Attie KM, Sherman ML, Sharma S> ;J. Clin. Oncol.. 2011-05-20
• Outcomes following sequential trials of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC).
  Bujold A, Massey C, Kim JJ, Brierley JD, Wong R, Cho C, Kassam Z, Dinniwell RE, Ringash J, Cummings B, Knox JJ, Sherman M, Dawson LA> ;J. Clin. Oncol.. 2011-05-20
• Effect of a soluble activin receptor type IIB on androgen-deprivation-induced effects on body composition.
  Lachey J, Koncarevic A, Ucran J, Pearsall RS, Sherman ML, Seehra J> ;J. Clin. Oncol.. 2009-05-20
• 164 citations
  Single‐Dose, Randomized, Double‐Blind, Placebo‐Controlled Study of ACE‐011 (ActRIIA‐IgG1) in Postmenopausal Women
  Jon Ruckle, Mark Jacobs, William Kramer, Amelia E. Pearsall, Ravindra Kumar, Kathryn W. Underwood, Jasbir Seehra, Yijun Yang, Carolyn H. Condon, Matthew L. Sherman> ;Journal of Bone and Mineral Research. 2009 Apr 1
• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial.
  Sherman M, Mazzaferro V, Amadori D, Seitz J, Moscovici M, Shan M, Nadel A, Voliotis D, Llovet JM, Bruix J> ;J. Clin. Oncol.. 2008-05-20
• 25 citations
  Clinical Studies with Tumour Necrosis Factor
  David R. Spriggs, Matthew L. Sherman, Emil Frei, Donald Kufe> ;Ciba Foundation Symposium. 2007 Sep 28
• 54 citations
  Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
  Anna Berkenblit, Joseph Paul Eder, David P. Ryan, Michael V. Seiden, Noriaki Tatsuta, Matthew L. Sherman, Thomas A. Dahl, Bruce J. Dezube, Jeffrey G. Supko> ;Clinical Cancer Research. 2007 Jan 15
• Join now to see all